Preliminary Results of Terazosin in the Treatment of Benign Prostatic Hypertrophy.
- Author:
Hyung Joo KIM
1
;
Kwang Soo LEE
Author Information
1. Department of Urology, Seoul Red Cross Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Terazosin;
Benign prostatic hypertrophy
- MeSH:
Humans;
Prostatic Hyperplasia*
- From:Korean Journal of Urology
1994;35(7):750-754
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The literature has suggested that alpha-receptor blockade may have therapeutic value in treating the symptoms of patients with benign prostatic hypertrophy. Terazosin is an alpha-1 adrenergic blocking agent approved by the FDA for the treatment of benign prostatic hypertrophy. We treated 30 patients with symptomatic benign prostatic hypertrophy in double- blind fashion using terazosin and placebo. In placebo group, mean total symptom score was decreased from 9.8 to 7.7 (p <0.0001), but was statistically significant in only obstructive symptom score. Changes in maximal and mean urinary flow rates were from 9.8 to 10.3 and from 4.9 to 5.3, respectively, but there was no statistical significance (p>0.05). In terazosin group, the symptom score changes in obstructive and irritative were from 6.1 to 3.3 and from 4.5 to 5.9 (p <0.0001), respectively, and changes in maximal and mean urinary flow rates were from symptoms 8.7 to 10.2 and from 4.2 to 5.9, respectively (p<0.0001). There were significant improvements in all parameters in terazosin group when compared with placebo group (p<0.05). It was concluded that terazosin is beneficial for treatment of obstructive symptoms in patients with benign prostatic hypertrophy.
